Metastasis suppression and enhancement of anti-tumour immunity by targeting the FSTL1-DIP2A axis

Cancer immunotherapy, currently a subject of much interest in oncology, has in fact featured in medical literature for centuries. Physicians throughout history noted the coincidence between acute infection and tumour regression, and even used localized infection as rudimentary immunotherapy (1).